

ND/CT04/FF/2020/19773

F. No. ND/CT/20/000039
Government of India

Tele No.011-23236965
Fax.No.011-23236973

Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated: 25.05.2020

To
M/s Glenmark Pharmaceuticals Limited,
B2, Mahalaxmi Chambers 22,
Bhula Bhai Desai Road,
Mumbai - 400026.

Subject:- Permission for conducting clinical study entitled, "A randomized open-label study to evaluate the efficacy and safety of Favipiravir and Umifenovir as compared to Favipiravir alone in moderate hospitalized adult Indian Covid-19 patients" - regarding.

Sir,

With reference to your Application No. ND/CT04/FF/2020/19773 dated 17.05.2020, please find enclosed herewith the permission in **Form CT-06, No. CT/ND/40/2020** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trial Rules, 2019** granted based on evaluation in consultation with Subject Expert Committee (SEC) as part of accelerated approval process in light of Covid 19 outbreak.

This permission is subject to the conditions, as mentioned below.

Yours faithfully



(Dr. V. G. Somani)
Central Licensing Authority

Condition of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be

- receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
 - (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
 - (xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
 - (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
 - (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
 - (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
 - (xix) The inclusion criteria should be clearly defined for inclusion of moderate COVID-19 patients in the study as per ICMR guidelines. The revised protocol should be submitted to CDSCO before initiating the study.**
 - (xx) CMC data as per the requirement like characterization details, certificate of analysis, stability data etc. should be submitted to CDSCO before initiation of clinical trial.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL
NEW DRUG**

The Central Licensing Authority hereby permits M/s Glenmark Pharmaceuticals Limited, B2, Mahalaxmi Chambers 22, Bhula Bhai Desai Road, Mumbai - 400026 India to conduct clinical trial of the investigational new drug as per **Protocol No. GPL/CT/2020/004/III, Version No. 2.0, Dated 21.05.2020** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:		Favipiravir & Umifenovir
Therapeutic class:		Antiviral
Dosage form:		Favipiravir Tablet & Umifenovir Capsule
Composition:		Favipiravir: Each film coated tablet contains: Favipiravir 200mg Umifenovir: Each capsule contains: Umifenovir 200mg
Indication:		Standard supportive care in hospitalized adult Indian patients with non-severe COVID-19
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
01	Dr. Meenakshi Bhattacharya, Government Medical College and Hospital, Near Makkai Gate, Panchakki Road, Aurangabad-431001, Maharashtra, India.	Institutional Ethics Committee, Department of Pharmacology, Government Medical College Aurangabad, Maharastra-431001, India ECR/314/Inst/MH/2013/RR-19
02	Dr. Jannakumar Khambhloiya, Smt. NHL Municipal Medical College Sardar Vallabhbhai Patel Institute of Medical Science and Research (SVPIMR) Ellisbridge, Ahmedabad 380015	Institutional Ethics Committee, SMT. NHL, Municipal Medical college, Ahmedabad (NHLIEC) Dept of pharmacology, first floor smt. NHL Municipal Medical College Ellisbrdge, Ahmedabad – 380006 ECR/245/Inst/GJ/2013/RR-16
03	Dr. Vishnu Rao, Apollo Hospital, Jupiter Hills, Hyderabad, Telangana, India	Institutional Ethics Committee, Apollo Hospitals Enterprise Limited, Hyderabad Apollo Research and Innovations, Jubilee Hills Apollo Health City, Hyderabad Shaikpet Hyderabad Telangana ECR/38/INST/AP/2013/RR-19

04	Dr. Krishnamoorthy, Apollo specialty Hospital, Vanagaram Plot No 64, Vanagaram, Ambattur Road, Ayanambakkam, Kil Ayanambakkam, Chennai600095, Tamil Nadu, India	Institutional Ethics Committee, Apollo specialty Hospital, Vanagaram Plot No 64, Vanagaram, Ambattur Road, Ayanambakkam, Kil Ayanambakkam, Chennai600095, Tamil Nadu, India ECR/37/INST/TN/2013/RR-19
05	Dr. Rajesh Gosavi, Government Medical College and Hospital, COVID Hospital and Critical Care Management, Hanuman Nagar, Ajni Rd, Medical Square Road, Nagpur- 440003, Maharashtra, India Department of medicine, Research room, Second floor, Hanuman Nagar, Ajni Rd, Medical Square Road, Nagpur- 440003, Maharashtra, India	Institutional Ethics Committee, Department of Pharmacology, Government Medical College, Nagpur ECR/43/Inst/MH/2013/RR-19
06	Dr. Atul Jindal, AIIMS, Covid Ward , Ayush Building Gate No.01 AIIMS G.E Road Tatibandh Raipur 492099 Chhattisgarh Department of Pediatric Medicine, Room No.1111, First Floor ,Medical College Complex, Gate no.05 AIIMS G.E Road Tatibandh Raipur492099 (C.G)	Institutional Ethics Committee, AIIMS Raipur Room No. 2103, 2nd Floor Medical College Complex, Gate No. 5, AIIMS, Raipur- 492099 (C G) Chhattisgarh, India. ECR/714/Inst/CT/2015/RR-18

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

New Delhi

Date: 25.05.2020

(Dr. V. G. Somani)
Central Licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002